Comparative Pharmacology
Head-to-head clinical analysis: INQOVI versus VIDAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INQOVI versus VIDAZA.
INQOVI vs VIDAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INQOVI is a combination of decitabine, a hypomethylating agent that inhibits DNA methyltransferase, and cedazuridine, a cytidine deaminase inhibitor that prevents degradation of decitabine, increasing its systemic exposure.
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA methyltransferase, causing hypomethylation of DNA and direct cytotoxicity in abnormal hematopoietic cells.
INQOVI (decitabine and cedazuridine) is administered orally once daily on days 1 through 5 of a 28-day cycle. The recommended dose is 1 tablet (35 mg decitabine and 100 mg cedazuridine) taken on an empty stomach.
75 mg/m2 subcutaneously or intravenously once daily for 7 days every 4 weeks.
None Documented
None Documented
The terminal elimination half-life of decitabine is approximately 2.5 hours (range 1.5-3.5 hours) following oral INQOVI administration. Cedazuridine has a similar half-life of about 2 hours. The half-lives are short, necessitating daily dosing for 5 days per cycle.
Terminal half-life: 5-7 hours (subcutaneous); 3-5 hours (intravenous); supports 7-day dosing cycle
Decitabine and cedazuridine are primarily excreted renally. Following oral administration, 58-64% of the decitabine dose and 93% of the cedazuridine dose are recovered in urine, with <2% in feces. Renal excretion is the main elimination pathway for both components.
Renal: 50-85% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Category C
Category C
Hypomethylating Agent
Hypomethylating Agent